Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

25.11.24 14:00 Uhr

Werte in diesem Artikel

CAMBRIDGE, Mass., Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 10:30 AM EST.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 6 months following the conference.

The Piper Sandler Healthcare Conference will take place December 3-5, 2024 in New York.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-36th-annual-piper-sandler-healthcare-conference-302315009.html

SOURCE Akebia Therapeutics, Inc.

Ausgewählte Hebelprodukte auf Akebia Therapeutics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Akebia Therapeutics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Akebia Therapeutics Inc

Analysen zu Akebia Therapeutics Inc

DatumRatingAnalyst
06.08.2019Akebia Therapeutics BuyH.C. Wainwright & Co.
11.07.2019Akebia Therapeutics BuyH.C. Wainwright & Co.
10.08.2018Akebia Therapeutics BuyNeedham & Company, LLC
06.06.2018Akebia Therapeutics BuyH.C. Wainwright & Co.
07.12.2017Akebia Therapeutics BuyBTIG Research
DatumRatingAnalyst
06.08.2019Akebia Therapeutics BuyH.C. Wainwright & Co.
11.07.2019Akebia Therapeutics BuyH.C. Wainwright & Co.
10.08.2018Akebia Therapeutics BuyNeedham & Company, LLC
06.06.2018Akebia Therapeutics BuyH.C. Wainwright & Co.
07.12.2017Akebia Therapeutics BuyBTIG Research
DatumRatingAnalyst
15.09.2017Akebia Therapeutics Sector PerformRBC Capital Markets
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Akebia Therapeutics Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"